Trial Profile
Safety and efficacy of Selexipag compared with Treprostinil in patients with Pulmonary Arterial Hypertension (PAH)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jul 2017
Price :
$35
*
At a glance
- Drugs Selexipag (Primary) ; Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- 12 Jul 2017 New trial record
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society